The Vape Tax: Why Taxing Safer Alternatives Like Cigarettes Is a Public Health Mistake

In 2023, California implemented a 12.5% excise tax on e-cigarettes—the same rate applied to combustible cigarettes in the state. The legislative logic was straightforward: nicotine products should be taxed to discourage use, generate revenue, and create a level playing field. But the economic logic collapses under scrutiny, because a 'level playing field' between products with radically different risk profiles is not neutral—it's discriminatory against the safer product. A tax that makes a combustible cigarette and an e-cigarette equally more expensive doesn't treat them equally. It makes the deadly product relatively more attractive by eliminating the price advantage of the safer alternative. This is not tax policy. It's public health policy by other means, and it's getting the incentives exactly backward.

The economic principle that should govern differential taxation of nicotine products is well-established and uncontroversial in every other domain of public health economics: tax harms proportionally to their magnitude. We tax alcohol based on alcohol content, not beverage volume. We tax carbon emissions based on carbon intensity, not energy output. The principle is that taxation should internalize externalities—making the price of a product reflect the social costs it imposes. Cigarettes impose enormous social costs: healthcare expenditures, lost productivity, environmental damage, secondhand smoke exposure. E-cigarettes impose some social costs—uncertain long-term health effects, youth initiation risk, environmental waste from disposables—but they're an order of magnitude lower on any reasonable estimate. Taxing them at the same rate as cigarettes is like taxing electric vehicles at the same rate as diesel trucks based on 'they're both vehicles.' The category error is obvious. The policy keeps being implemented anyway.

The empirical evidence on how vape taxes affect smoking behavior is accumulating rapidly—and it's alarming. A 2024 study in the *Journal of Health Economics* analyzed the effects of e-cigarette taxes across U.S. states and found that a 10% increase in e-cigarette taxes was associated with a 2–3% increase in cigarette purchases, suggesting that vapers respond to higher vaping costs by switching back to smoking. Another study in *Health Economics* found that state-level e-cigarette taxes were associated with increased youth smoking rates—precisely the opposite of the intended effect—because the taxes made vaping less affordable for price-sensitive youth who might otherwise have chosen it over smoking. The mechanism is the substitution effect that basic economics predicts: when you raise the price of Product B (which competes with Product A), consumers shift toward Product A. When Product A kills people and Product B doesn't, that shift has a body count.

The revenue argument for vape taxes is politically seductive and substantively shortsighted. Governments facing budget gaps see nicotine as an easy revenue source—users are addicted, demand is inelastic, and the political opposition is diffuse. But vape taxes that drive vapers back to smoking generate healthcare costs that dwarf the tax revenue. A single case of lung cancer costs the healthcare system hundreds of thousands of dollars; a single COPD patient costs tens of thousands annually for decades. The short-term revenue gain from vape taxes is more than offset by the long-term healthcare costs of the smoking they encourage—but government accounting doesn't connect these line items, so the revenue looks like free money and the costs are somebody else's problem. This is fiscal myopia dressed up as fiscal responsibility.

The optimal tax framework for nicotine products is a risk-proportionate excise tax that creates a meaningful price gradient: cigarettes taxed highest, heated tobacco products taxed at an intermediate rate, e-cigarettes taxed lower, and pharmaceutical NRT taxed lowest or not at all. This framework would create a financial incentive for smokers to move down the risk continuum, using price signals to achieve what public health education alone cannot—behavior change at the population level. The UK has moved closest to this model, with differential tax rates that maintain a significant price advantage for vaping over smoking. The results speak for themselves: the UK has one of the highest vaping rates and fastest-smoking-decline rates in the developed world. The tax differential is not the only factor, but it's an important one—every economic analysis confirms that relative price matters.

The political obstacles to risk-proportionate taxation are formidable. Tobacco tax revenue is substantial and, in many jurisdictions, earmarked for popular programs—healthcare, education, children's health insurance. Reducing cigarette tax revenue by encouraging smokers to switch to lower-taxed alternatives threatens those programs in the short term. The tobacco industry, understanding this, has weaponized the revenue argument: 'if everyone switches to vaping, how will you fund CHIP?' The industry that spent decades fighting tobacco taxes now poses as the guardian of the revenue they generate—a position of staggering cynicism that is, unfortunately, effective. The path to risk-proportionate taxation requires decoupling health program funding from tobacco revenue, so that the fiscal incentive to maintain smoking is eliminated. This is a structural reform that goes beyond tax policy into the architecture of public finance.

The vape tax debate is ultimately a test of whether governments are serious about harm reduction or merely serious about revenue. A government that taxes cigarettes at $3 per pack and e-cigarettes at an equivalent rate is sending an unambiguous signal to nicotine users: we don't care which product you use, we just want our cut. A government that taxes cigarettes at $3 per pack and e-cigarettes at a rate that reflects their lower risk—perhaps $0.50 per equivalent nicotine dose—is sending a different signal: we'd prefer you use neither, but if you're going to use one, the safer option is the cheaper one for a reason. The difference between these two signals, expressed across populations and over decades, is measurable in cancer cases, cardiovascular events, and premature deaths. Tax policy is health policy. The question is whether policymakers will start acting like they believe it.